Clinical Trials Browser

Small Cell Lung Carcinoma

NCT06252753 2025-12-26

LIVER-R

Recruiting

4,490 enrolled

Gastrointestinal

Hepatobiliary Cancers

NCT06117891 2025-11-12

REFINE-IO

Recruiting

300 enrolled

Gastrointestinal

Unresectable Hepatocellular Carcinoma

NCT06826677 2025-06-24

ARAL

Completed

71 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04667312 2023-10-02

CODAK

Completed

115 enrolled

Thoracic

Non-Small Cell Lung Cancer NSCLC

NCT04364776 2023-09-28

Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.

Unknown

100 enrolled

Thoracic

Lung Neoplasms

NCT02154490 2023-06-01

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Completed

1,864 enrolled 12 charts

Recurrent Squamous Cell Lung Carcinoma

NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

Unknown

1,800 enrolled

DermatologicGenitourinaryThoracic

Kidney Neoplasms, Lung Neoplasms, Melanoma

NCT04359199 2023-02-10

QUASAR

Unknown

42 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Deglutition Disorders, Head and Neck Neoplasms, Oropharyngeal Neoplasms

NCT04285866 2022-06-07

S-REAL

Completed

245 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04672759 2020-12-17

A Real-world Study of Durvalumab for Lung Cancer in China

Unknown

100 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

Clinical Trials

ARSENAL

LIVER-R

REFINE-IO

ARAL

CODAK

Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Microbiome Immunotherapy Toxicity and Response Evaluation

QUASAR

S-REAL

A Real-world Study of Durvalumab for Lung Cancer in China